Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Direct Integrative Care

Introduction

Low-dose naltrexone (LDN) has emerged as one of the most versatile and promising off-label therapies in integrative and functional medicine. Originally approved at doses of 50–150 mg per day for the treatment of opioid and alcohol use disorders, naltrexone has attracted increasing attention at much lower doses—typically 0.5 to 4.5 mg per day—for its immunomodulatory, anti-inflammatory, and analgesic properties (Younger et al., 2014). Over the past two decades, clinicians in integrative medicine have incorporated LDN into treatment protocols for conditions including chronic pain, autoimmune disease, mast cell activation syndrome (MCAS), neuroinflammation, and post-viral syndromes such as long COVID.

This article synthesizes the key mechanisms, clinical considerations, and evidence supporting the use of LDN as a foundational tool in integrative practice. It draws on both peer-reviewed literature and clinical experience to address individualized dosing, the relationship between LDN and the endorphin system, its role in MCAS, neuropathic pain, neuroimmune modulation, and its emerging relevance in integrative oncology. Throughout, the emphasis remains on realistic expectations, patient safety, and the importance of individualized care through a qualified clinician.

Mechanism of Action: TLR4 Antagonism and Microglial Modulation

One of the most well-characterized mechanisms of LDN involves its antagonism of Toll-like receptor 4 (TLR4) on microglia and macrophages. At standard doses, naltrexone functions primarily as an opioid receptor antagonist. However, at low doses, it exhibits a paradoxical shift in receptor affinity, binding preferentially to TLR4 rather than opioid receptors (Younger et al., 2014; Hutchinson et al., 2008). TLR4 activation by damage-associated molecular patterns and lipopolysaccharide (LPS) drives the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. By antagonizing TLR4, LDN reduces microglial activation and downstream neuroinflammation—a mechanism that has particular relevance in conditions characterized by central sensitization, including fibromyalgia, chronic fatigue syndrome, and neuropathic pain (Younger et al., 2014; Grace et al., 2015).

Preclinical studies using the non-opioid enantiomer (+)-naltrexone have demonstrated neuroprotective effects through selective TLR4 blockade, including reversal of neuropathic pain and reduction of microglial activation markers in nerve injury models (Hutchinson et al., 2008). While clinically available naltrexone is the (-)-enantiomer with activity at both opioid and TLR4 receptors, the dual mechanism at low doses appears to account for its broad anti-inflammatory profile.

Mechanism of Action: Endorphin Modulation

The second major proposed mechanism of LDN involves transient opioid receptor blockade and compensatory upregulation of endogenous opioid production. At low doses, naltrexone briefly blocks mu-opioid receptors, after which the body is thought to mount a rebound increase in β-endorphin and met-enkephalin levels (Kumari et al., 2023). This endorphin upregulation has been proposed to contribute to improvements in mood, pain perception, and immune regulation.

However, the endorphin hypothesis remains an area of active investigation. A 2021 study by Benson and colleagues found no significant changes in β-endorphin levels or POMC neuron activity in mice treated with LDN, suggesting that the clinical benefits of LDN may not be fully explained by the endorphin rebound model alone (Benson et al., 2021). This finding highlights the importance of recognizing that LDN likely works through multiple, overlapping pathways—including TLR4 modulation, glial cell regulation, and the opioid growth factor (OGF)–OGF receptor axis—rather than any single mechanism.

Individualized Dosing: The Clinical Imperative

One of the most critical and often underappreciated aspects of LDN therapy is the need for individualized dosing. The conventional starting dose of 1.5 mg with titration to 4.5 mg may be appropriate for many clients, but a growing subset of individuals—particularly those with MCAS, long COVID, or complex chronic illness—cannot tolerate standard doses and may require microgram-level or even lower starting doses.

When clients develop anxiety, sleep disruption, tension, or symptom flares on LDN, the dose may exceed their current endorphin reserve or immune regulatory capacity. In clinical practice, this pattern often reflects a dose mismatch rather than a fundamental intolerance to the medication. The appropriate response is typically to discontinue LDN until symptoms resolve, then restart at a substantially lower dose under clinician guidance (Martin et al., 2022). The guiding principle is that the right question is not “What is the dose?” but rather “What is the right dose for this individual?”

LDN and Mast Cell Activation Syndrome

MCAS has emerged as a central consideration in the clinical use of LDN, both as a target condition and as a factor influencing tolerability. MCAS is characterized by inappropriate activation and degranulation of mast cells, leading to multisystem symptoms including histamine-driven inflammation, gastrointestinal dysfunction, neuropsychiatric symptoms, and chemical sensitivities (Weinstock et al., 2018). Clinicians who treat MCAS frequently observe that it overlaps with fibromyalgia, chronic fatigue syndrome, dysautonomia (including POTS), hypermobility spectrum disorders, and small intestinal bacterial overgrowth (SIBO).

In a clinical series of 116 MCAS clients treated with LDN, Weinstock reported that approximately 60% experienced improvement in symptoms including abdominal pain, joint and muscle pain, gastrointestinal complaints, and restless leg syndrome, while roughly 20% discontinued due to side effects—a rate consistent with the heightened medication sensitivity characteristic of MCAS (Weinstock, 2021). The proposed mechanism for LDN benefit in MCAS involves reduction of excessive T-cell dysfunction and downstream mast cell calming, as well as its broader immunomodulatory and neuroinflammatory effects.

Importantly, clients with MCAS may have diminished endorphin reserves or altered endorphin responsiveness, making them more prone to LDN side effects at conventional doses. This clinical pattern underscores the need for ultra-low starting doses in the MCAS population.

LDN in Neuropathic Pain

LDN has demonstrated particular promise as a tool for neuropathic pain management. In a scoping review of non-cancer centralized pain conditions, LDN was found to have relevance in conditions where neuroinflammation and central sensitization are implicated, including fibromyalgia, complex regional pain syndrome (CRPS), and neuropathic pain syndromes (Dieckmann et al., 2023). The proposed mechanism involves TLR4-mediated reduction of microglial activation in the central nervous system, leading to decreased pro-inflammatory cytokine production and reduced central sensitization.

Preclinical data support the use of LDN specifically in trigeminal neuralgia. De Oliveira and colleagues (2020) demonstrated that low-dose naltrexone completely reversed facial mechanical allodynia in a rat model of trigeminal neuralgia after ten days of treatment, with modulation of spinal cord BDNF and IL-10 levels. A subsequent study confirmed that combining LDN with carbamazepine produced synergistic antiallodynic effects while potentially allowing reduction of carbamazepine dosing and its associated side effects (Scientific Reports, 2025).

In a retrospective cohort study of 93 chronic pain clients, LDN showed broad applicability across multiple pain diagnoses, with the strongest responses in conditions featuring inflammatory or nociplastic components—consistent with its mechanisms involving cytokine modulation, glial cell regulation, and endorphin production (Journal of Pain Research, 2025).

LDN in Fibromyalgia

Fibromyalgia is among the most studied conditions in the LDN literature. Younger and colleagues (2013) conducted a randomized, double-blind, placebo-controlled, crossover trial in 31 women with fibromyalgia and found that 4.5 mg of LDN daily produced a statistically significant 28.8% reduction in pain compared with 18.0% for placebo. The researchers concluded that LDN demonstrated a specific and clinically beneficial impact on fibromyalgia pain that was inexpensive, safe, and well-tolerated.

A larger Danish randomized controlled trial (Due Bruun et al., 2024) using 6 mg naltrexone in 100 women with fibromyalgia did not demonstrate superiority over placebo for pain reduction, though it did suggest possible benefits for memory-related symptoms. Systematic reviews and meta-analyses have concluded that while the evidence is promising, larger and more methodologically rigorous trials are still needed to definitively establish LDN’s efficacy in fibromyalgia (Mikkelsen et al., 2023; EPain, 2024).

LDN in Long COVID and Post-Viral Syndromes

The COVID-19 pandemic has generated significant clinical interest in LDN as a potential therapy for post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as long COVID. Many long COVID presentations share pathophysiological features with ME/CFS, including neuroinflammation, central sensitization, immune dysregulation, and post-exertional malaise—all of which represent potential targets for LDN’s dual mechanism of action (O’Kelly et al., 2023).

A systematic review of LDN in long COVID found moderate pooled effects for fatigue reduction, though the authors noted that the current published literature is limited by study design biases and small sample sizes (medRxiv, 2025). Multiple randomized controlled trials are currently underway, including a double-blind, placebo-controlled trial through British Columbia’s Complex Chronic Diseases Program (NCT05430152), which should provide more definitive evidence regarding LDN’s role in this population.

Clinically, clients with long COVID often exhibit the same heightened neurological sensitivity and medication intolerance seen in MCAS populations, reinforcing the importance of conservative “start low, go slow” dosing protocols.

LDN in Integrative Oncology: Promising but Not Proven

The role of LDN in oncology remains one of the most compelling yet preliminary areas of investigation. Dr. Burton M. Berkson pioneered the use of intravenous alpha-lipoic acid (ALA) combined with oral LDN—known as the Berkson ALA/N protocol—for clients with advanced cancer and liver disease. Published case reports describe long-term survival in clients with metastatic pancreatic cancer, hepatocellular carcinoma, and stage IV renal cell carcinoma treated with this integrative protocol (Berkson et al., 2006; Berkson et al., 2009; Berkson, 2018).

The proposed oncologic mechanisms of LDN involve modulation of the opioid growth factor (OGF)–OGF receptor axis, which regulates cell proliferation, as well as immune enhancement through endorphin upregulation and anti-inflammatory effects. A recent preclinical study demonstrated that LDN inhibited colorectal cancer progression and promoted apoptosis by increasing M1-type macrophage polarization and activating the Bax/Bcl-2/caspase-3/PARP pathway (Dalgleish, 2022).

However, it must be emphasized that there are currently no large placebo-controlled randomized controlled trials of LDN for cancer outcomes. The only completed RCT—a Duke University glioma trial (Peters et al., 2022)—evaluated quality of life and fatigue during concurrent chemotherapy and radiation, not tumor response. LDN should not be promoted as a cancer treatment, but it may have theoretical and investigational relevance as part of a broader integrative oncology approach.

Practical Clinical Considerations

Several practical pearls emerge from clinical experience with LDN. Sleep disruption—whether LDN is taken at bedtime, in the morning, or during the day—may indicate that the dose exceeds the client’s current tolerance and should prompt dose reassessment. When new symptoms appear after starting LDN, the recommended approach is to stop the medication until symptoms resolve, evaluate for alternative causes, and consider restarting at a lower dose. LDN intolerance often reflects dose mismatch rather than medication failure. Symptoms such as dry eyes and dry mouth are not commonly associated with LDN and warrant evaluation for other etiologies.

LDN is not a standalone therapy. It works best as part of a comprehensive integrative treatment plan that addresses root causes, nutritional status, gut health, hormonal balance, environmental exposures, and lifestyle factors. Furthermore, all LDN decisions should be made in collaboration with a qualified clinician who understands the client’s full medical history, current medications, sensitivities, and treatment goals.

The Role of Patient Education

Responsible patient education is essential to the appropriate use of LDN. Online communities can be valuable resources for shared experience, but they can also propagate misinformation, inappropriate dosing recommendations, and unrealistic expectations. Structured educational communities with clear rules about the boundaries between peer support and medical advice serve an important role in helping clients navigate LDN therapy. Platforms such as Facebook, while widely used, present challenges for health-related communities due to content moderation policies that may restrict discussion of dosing, sourcing, and clinical details.

The goal of education is to empower clients with organized, evidence-informed knowledge so they can have productive conversations with their clinicians and make well-informed decisions about their care.

Conclusion

LDN represents a flexible, generally well-tolerated, and potentially powerful tool in the integrative medicine toolkit. Its dual mechanism—TLR4-mediated anti-inflammatory effects and endorphin modulation—provides a rationale for its application across a broad range of conditions including chronic pain, autoimmune disease, MCAS, neuroinflammation, post-viral syndromes, and, cautiously, integrative oncology. However, LDN is not one-size-fits-all. Individualized dosing, realistic expectations, careful monitoring, and collaboration with a qualified clinician are essential. For sensitive populations—particularly those with MCAS or long COVID—starting at ultra-low doses may be the difference between therapeutic success and perceived medication failure.

Clients interested in exploring whether LDN may be appropriate for their condition are encouraged to schedule a consultation through Direct Integrative Care.

References

Benson BM, Shah S, Tobin S, et al. Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and β-endorphin. J Neurosci. 2021;41(27):5898–5911. doi:10.1523/JNEUROSCI.0170-21.2021

Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous α-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006;5(1):83–89. doi:10.1177/1534735405285901

Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (α-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther. 2009;8(4):416–422. doi:10.1177/1534735409352082

Berkson BM. The long-term survival of a patient with stage IV renal cell carcinoma following an integrative treatment approach including the intravenous α-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2018;17(3):986–993. doi:10.1177/1534735417740629

de Oliveira CL, Medeiros LF, de Souza VS, et al. Low-dose naltrexone reverses facial mechanical allodynia in a rat model of trigeminal neuralgia. Neurosci Lett. 2020;736:135248. doi:10.1016/j.neulet.2020.135248

Dieckmann G, Engelman E, Engelman D. Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270–1284. doi:10.1093/pm/pnad089

Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6:e31–e39. doi:10.1016/S2665-9913(23)00278-3

Grace PM, Strand KA, Galer EL, et al. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci U S A. 2016;113(24):E3441–E3450. doi:10.1073/pnas.1602070113

Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83–95. doi:10.1016/j.bbi.2009.08.004

Kučić N, Rački V, Šverko R, et al. Immunometabolic modulatory role of naltrexone in BV-2 microglia cells. Int J Mol Sci. 2021;22(16):8429. doi:10.3390/ijms22168429

Kumari R, Kareem ZY, McLaughlin PJ. Acute low dose naltrexone increases β-endorphin and promotes neuronal recovery following hypoxia-ischemic stroke in type-2 diabetic mice. Neurochem Res. 2023;48:2835–2846. doi:10.1007/s11064-023-03938-4

Martin SJ, McAnally HB, Okediji P, et al. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study. Pain Manag. 2022;12(4):447–457. doi:10.2217/pmt-2021-0122

Naik H, Cooke E, Boulter T, et al. Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia. BMJ Open. 2024;14(5):e084460. doi:10.1136/bmjopen-2024-084460

O’Kelly B, Vidal L, McHugh T, et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol. 2023;124:110879. doi:10.1016/j.intimp.2023.110879

Peters D, Levin A, Engelman D, et al. Low-dose naltrexone for quality of life in glioma: a randomized controlled trial. J Clin Oncol. 2022;40(16_suppl):2049.

Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr2017221405. doi:10.1136/bcr-2017-221405

Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734

Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2

About Dr. Kim

Dr. Yoon Hang “John” Kim is a board-certified physician with over 20 years of experience in integrative and functional medicine. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. Dr. Kim is the author of three books and more than 20 peer-reviewed articles, and has helped establish integrative medicine programs at academic medical centers nationwide.

Professional: www.yoonhangkim.com | Clinical: Direct Integrative Care

Disclaimer

This article is for educational and informational purposes only and does not constitute individualized medical advice. LDN is an off-label therapy. All treatment decisions should be made in consultation with a qualified healthcare provider who is familiar with the client’s complete medical history.